Asieris Receives Approval for CEVIRA as the First Non-Invasive Therapy for Cervical Precancerous Lesions in China Asieris Pharmaceuticals has achieved a significant milestone with the approval of CEVIRA in China, marking the first non-invasive therapy for cervical precancerous lesions.

Asieris Receives Approval for CEVIRA as the First Non-Invasive Therapy for Cervical Precancerous Lesions in China #China #N/A #Photocure #CEVIRA #Asieris

Asieris Announces EMA Acceptance for CEVIRA Marketing Authorization in Europe Asieris Pharmaceuticals communicates that the EMA has accepted the application for CEVIRA, a new photodynamic therapy for HSIL. Discover what this means for treatment options in Europe.

Asieris Announces EMA Acceptance for CEVIRA Marketing Authorization in Europe #Norway #Oslo #Photocure #CEVIRA #Asieris